MacroGenics, Inc. (MGNX) Stock Price & Analysis

MacroGenics, Inc. (MGNX) is trading at USD 2.53, up 2.43% today, as of October 29, 2026 at 16:00 UTC (US market open; quotes may be delayed), according to Nexqual market data.

MGNX last closed at USD 2.47; today's session has ranged USD 2.43–2.59 on volume of 399,457 shares. Market capitalization is $161.16M, with a 52-week range of USD 1.29–5.08 (NMS). Source: Nexqual, retrieved October 29, 2026 at 16:06 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MGNX.md

Key facts (MGNX)

• Last four reported quarters (through Jun 30, 2026): revenue $168M, net income -$14.6M (-8.7% margin), free cash flow -$65.5M (SEC filings).
• Insider open-market sales, last ~7 months: 1 Form 4 filings, $129K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.43 on a 1–5 scale) (7 analysts), mean target USD 8 (range 4–11).
• Total return with dividends: 1Y +49.7% vs S&P 500 +13.2%; 5Y -87.0% vs S&P 500 +79.2%.
• Next earnings: 2026-11-12, EPS estimate USD -0.13, revenue estimate $39.2M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MGNX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (MGNX)

P/S 1.0x · P/B 3.8x · FCF yield -40.67% · Earnings yield -9.05%

Insider sales (SEC Form 4, open-market, last ~7 months) (MGNX)

1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (MGNX)

Consensus Buy (mean 2.43 on a 1–5 scale), 7 analysts; mean target USD 8 (low 4, high 11).

Rating changes, last 120 days:

Total return (dividends reinvested) (MGNX)

MGNX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

MGNX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

MGNX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 9, 2026.

Companies that name MGNX in their SEC reports

MGNX company outlook (results filed Aug 13, 2026)

• “Guidance : MacroGenics anticipates that its pro forma cash, cash equivalents and marketable securities of $327 million as of June 30, 2026, plus other projected future payments from partners, will support the Company's cash runway through 2028.”

Quoted word-for-word from the SEC 8-K results press release.

MGNX analyst estimates and revisions

MGNX options: expected move

Options price a move of about ±27.1% (±$0.67) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±13.9% on average.

30-day implied volatility 95.3% vs 155.8% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 16:06 UTC)

Technical Analysis (MGNX)

Nexqual's technical model rates MGNX "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 29, 2026 at 16:06 UTC.

Analyst Ratings (MGNX)

Wall Street analysts rate MGNX "Buy" based on 7 analysts, with a mean price target of USD 8 (range USD 4–11), per Nexqual as of October 29, 2026 at 16:06 UTC.

Earnings (MGNX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 16:06 UTC.

Financials & Fundamentals (MGNX)

Source: Nexqual, October 29, 2026 at 16:06 UTC.

Financial Health Score (MGNX)

Nexqual rates MacroGenics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 16:06 UTC.

Ownership (MGNX)

Source: Nexqual, October 29, 2026 at 16:06 UTC.

Leadership (MGNX)

MacroGenics, Inc. is led by Eric Blasius Risser, CEO, President & Director, per Nexqual as of October 29, 2026 at 16:06 UTC.

Major Backers & Investors (MGNX)

Notable institutional backers of MacroGenics, Inc. include Armistice Capital, LLC, Renaissance Technologies, Acadian Asset Management. LLC, according to Nexqual as of October 29, 2026 at 16:06 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 16:06 UTC.

From MacroGenics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)

Key Strengths & Strategy (as disclosed to the SEC)

• However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.
• Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
• We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms.
• DART and TRIDENT Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single target as with traditional mAbs.

Partnerships

• In connection with the sale, we entered into an agreement with TerSera to provide manufacturing services to produce MARGENZA.
• In June 2025, we received $70.0 million upon entering into a royalty purchase agreement with Sagard Healthcare Partners (Sagard) in exchange for a capped royalty interest on future global net sales of ZYNYZ.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.
• Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals.
• We and our collaborators are subject to various healthcare laws, and our failure, or the failure of our collaborators, to comply with those laws could result in significant penalties and adversely affect our business, operations and financial condition.
• Our employees and personnel may integrate generative AI technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 16:06 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt